SCNI - Scinai Immunotherapeutics Ltd

SCNI - Scinai Immunotherapeutics Ltd

https://www.scinai.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

PR Newswire • 1 year, 2 months ago • score: -0.06

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing ... PR ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$4.76

52W Low

$1.40

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.86

Valuation

Attractive

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

0.38

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.05

EV/Revenue (<3 favorable)

7.41

P/S (TTM) (<3 favorable)

2.28

P/B (<3 favorable)

0.67

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

10.26%

Institutions (25–75% balanced)

16.32%

Shares Outstanding

999,920

Float

2,442,673,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

658,000

Gross Profit (TTM)

-580,000

EPS (TTM)

4.00

Profit Margin (>10% good)

7.29%

Operating Margin (TTM) (higher better)

-10.99%

ROE (TTM) (>15% strong)

1.77%

EPS YoY (Quarterly) (>10% good)

0.87

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0618

Previous

-0.0685

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025